Ardelyx (ARDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Ardelyx reported revenue of $110.33 million for the quarter ended September 2025, reflecting a 12.3% increase year-over-year and a surprise of +10.52% over the Zacks Consensus Estimate of $99.83 million [1] - The earnings per share (EPS) was reported at $0, matching the EPS from the same quarter last year, with a surprise of +100% compared to the consensus estimate of -$0.06 [1] Revenue Breakdown - Product sales, net amounted to $105.52 million, exceeding the average analyst estimate of $97.49 million, representing a year-over-year increase of +14.6% [4] - Product sales for IBSRELA reached $78.16 million, surpassing the average estimate of $70.88 million [4] - Product sales for XPHOZAH were reported at $27.36 million, slightly above the average estimate of $26.61 million [4] - Licensing revenue was $0.03 million, below the average estimate of $0.18 million, but showed a year-over-year increase of +25% [4] - Non-cash royalty revenue related to future royalties was $4.79 million, significantly exceeding the average estimate of $1.29 million, with a year-over-year change of +492% [4] Stock Performance - Ardelyx shares have returned -7.5% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]